Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 10

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 10
---
 to the conditions contained herein;

NOW THEREFORE THIS AGREEMENT WITNESSESthat the Parties (as hereinafter defined) hereby covenant and agree as follows: ARTICLE 1 INTERPRETATION

| 1.1 | Definitions |

In this Agreement (including the Schedules and the recitals hereto), unless the context otherwise requires:

| (a) | “Acceptable Confidentiality Agreement” means a confidentiality agreement entered into after                                                                                                                                                  
 the date hereof with the Company on customary terms that (a) include non-use and confidentiality covenants, customary exclusions from the definition of “Confidential Information,” and obligations to protect and restrict disclosure       
 of confidential information at least to a commercially reasonable standard and reasonably acceptable to Purchaser (it being understood that such agreement need not contain any “standstill” or similar provisions or otherwise prohibit the 
 making of any Acquisition Proposal), and (b) do not prohibit the Company from providing any information to the Purchaser in accordance with Article 6;                                                                                       |

| (b) | “Accounting Firm” has the meaning set out in Section 2.8(e); |

| (c) | “Acquisition Proposal” means, other than the Contemplated Transactions or any Permitted                                                                                                                                                                  
 Disposition, any offer, proposal, inquiry or public announcement, whether written or oral, from any person or group of persons other than the Purchaser (or an affiliate of the Purchaser or any person acting jointly or in concert with the Purchaser) 
 relating to any:                                                                                                                                                                                                                                         |

| (i) | direct or indirect sale, disposition, issuance or acquisition of shares or other equity interests (or                                                                                                                                                    
 securities convertible into or exercisable for such shares or interests) that, when taken together with any securities of the Company held by the proposed acquiror, and any person acting jointly or in concert with such acquiror and assuming the     
 conversion of any convertible securities held by the proposed acquiror and any person acting jointly or in concert with such acquiror, would constitute beneficial ownership representing 20% or more of any class of equity or voting securities of the 
 Company or its Subsidiary;                                                                                                                                                                                                                               |

| (ii) | any direct or indirect sale, disposition, acquisition or purchase (or any lease, long-term supply agreement,                                                                                                                                             
 joint venture or other arrangement having the same economic effect as a sale, disposition, acquisition or purchase) of assets of any member of the Company (including, without limitation, the shares